drugset

Drugs / BCMA/CD19 Chimeric Antigen Receptor T (CAR T) cells

Follow last change Dec 2025 re-read 3 minutes ago

BCMA/CD19 Chimeric Antigen Receptor T (CAR T) cells

Developed for: Sjogren syndrome · systemic lupus erythematosus
Investigated by: Essen Biotech

Trials 1

today NCT06428188 · Ph 1/2

20252026

Phase	Registry id	Dates	Indication	Sponsor	Status	Outcome
Phase 1/2	NCT06428188	May 2024 → Dec 2025 overdue	Sjogren syndrome, systemic lupus erythematosus	Essen Biotech	Recruiting	No outcome recorded

Evidence & citations 3 cited values

Every value below carries the sentence it was read from. 1 source stands behind the page.

Field	Value	Cited text
Known as	BCMA/CD19 Chimeric Antigen Receptor T (CAR T) cells	“The intervention in this clinical trial involves a novel approach using BCMA/CD19 Chimeric Antigen Receptor T (CAR T) cells combined with chemotherapy.” NCT06428188 ↗
Modality	Cell therapy	“chimeric antigen receptor T cell immunotherapy (CAR-T)” NCT06428188 ↗
Route	Intravenous	“BCMA/CD19 CAR T cells intravenously (IV) over a duration of 10-20 minutes on day 0” NCT06428188 ↗